mRNA |
crizotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.086 |
0.01 |
mRNA |
BRD-K34485477 |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
0.01 |
mRNA |
CIL41 |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.02 |
mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.074 |
0.02 |
mRNA |
salermide:PLX-4032 (12:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.092 |
0.02 |
mRNA |
IU1 |
CTRPv2 |
pan-cancer |
AAC |
0.095 |
0.02 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.08 |
0.02 |
mRNA |
selumetinib:BRD-A02303741 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.086 |
0.02 |
mRNA |
NPK76-II-72-1 |
GDSC1000 |
pan-cancer |
AAC |
0.071 |
0.02 |
mRNA |
serdemetan:SCH-529074 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.085 |
0.02 |